论文部分内容阅读
目的观察二甲双胍(Met)对T2DM患者尿单核细胞趋化蛋-1(MCP-1)排泄的影响,探讨其肾脏保护作用。方法 121例T2DM患者(T2DM组)根据抗糖尿病治疗方案分为胰岛素治疗(Ins)组和磺脲类治疗(SUs)组,上述两组再根据是否联合服用Met分别分为Ins治疗亚组和Ins联合Met治疗亚组,以及SUs治疗亚组和SUs联合Met治疗亚组,另选择24名健康对照(NC)组,比较各组FPG、2hPG、HbA1c、UAlb/Cr和尿MCP-1/Cr(UMCR)等指标。结果与NC组比较,T2DM组FPG[(4.85±0.10)vs(7.21±0.14)mmol/L]、2hPG[(5.24±0.22)vs(9.71±0.31)mmol/L]、HbA1c[(5.22±0.06)%vs(7.03±0.10)%]、UAlb/Cr[(13.63±1.03)vs(27.68±3.99)mg/g]和UMCR[(30.71±1.83)vs(95.96±17.10)pg/ng]升高(P<0.05);与Ins治疗亚组比较,Ins联合Met治疗亚组UAlb/Cr[(42.96±6.24)vs(10.48±1.98)mg/g]和UMCR[(116.2±10.47)vs(27.42±4.45)pg/ng]降低(P<0.05);与SUs治疗亚组比较,SUs联合Met治疗亚组UAlb/Cr[(52.43±7.80)vs(18.31±5.70)mg/g]和UMCR[(240.8±12.77)vs(53.58±8.11)pg/ng]降低(P<0.05)。相关分析显示,T2DM患者UAlb/Cr是UMCR的独立相关因素(P<0.001)。结论Met可减少T2DM患者尿MCP-1的排泄,该作用可能与其肾脏保护有关。
Objective To observe the effect of metformin on the excretion of urinary monocyte chemoattractant protein-1 (MCP-1) in T2DM patients and explore its renal protective effect. Methods Twenty-two T2DM patients (T2DM group) were divided into Ins group and SUs group according to anti-diabetic treatment regimen. The two groups were divided into Ins group and Ins group Met subgroup, SUs subgroup and SUs combined with Met subgroup. Another 24 healthy control (NC) groups were selected to compare FPG, 2hPG, HbA1c, UAlb / Cr and urine MCP-1 / Cr UMCR) and other indicators. Results Compared with NC group, FPG [(4.85 ± 0.10) vs (7.21 ± 0.14) mmol / L], 2hPG [(5.24 ± 0.22) vs (9.71 ± 0.31) mmol / L], HbA1c [(5.22 ± 0.06) ) and UMCR [(30.71 ± 1.83) vs (95.96 ± 17.10) pg / ng] in UAb / Cr [(13.63 ± 1.03) vs (27.68 ± 3.99) mg / (42.96 ± 6.24) vs (10.48 ± 1.98) mg / g] and UMCR [(116.2 ± 10.47) vs (27.42 ± (52.43 ± 7.80 vs (18.31 ± 5.70) mg / g] and UMCR [(240.8 ± 4.45) pg / ng] in SUs plus Met group (P <0.05) ± 12.77 vs 53.58 ± 8.11 pg / ng] (P <0.05). Correlation analysis showed that UAlb / Cr in T2DM patients were independently associated with UMCR (P <0.001). Conclusions Met can reduce urinary MCP-1 excretion in T2DM patients, which may be related to its renal protection.